Literature DB >> 9719884

The evidence for the management of endometriosis.

C Farquhar1, C Sutton.   

Abstract

This review article has focussed on identifying the evidence from randomized controlled trials for the medical and surgical management of endometriosis. A critical summary of the medical management has shown that there is little difference in effectiveness of various medical treatments, but there are differences in the side-effect profiles. Few randomized controlled trials have been undertaken in surgery, but these have shown that surgical management is effective in the management of both painful symptoms and subfertility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9719884     DOI: 10.1097/00001703-199808000-00007

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  5 in total

1.  Endometriosis. Emphasis on medical treatment is misleading.

Authors:  Kevin D Jones; Christopher Sutton
Journal:  BMJ       Date:  2002-01-12

2.  Endometrial pinopode and alphavbeta3 integrin expression is not impaired in infertile patients with endometriosis.

Authors:  Jaume Ordi; Montserrat Creus; Roser Casamitjana; Antonio Cardesa; Juan A Vanrell; Juan Balasch
Journal:  J Assist Reprod Genet       Date:  2003-11       Impact factor: 3.412

3.  Long-term follow-up of a controlled trial of laser laparoscopy for pelvic pain.

Authors:  K D Jones; P Haines; C J Sutton
Journal:  JSLS       Date:  2001 Apr-Jun       Impact factor: 2.172

4.  Medical management of recurrent endometrioma with long-term norethindrone acetate.

Authors:  Ozgul Muneyyirci-Delale; Jenny Anopa; Cassandra Charles; Deepali Mathur; Rudolph Parris; Jed B Cutler; Ghadir Salame; Ovadia Abulafia
Journal:  Int J Womens Health       Date:  2012-03-30

5.  Comparing long term impact on ovarian reserve between laparoscopic ovarian cystectomy and open laprotomy for ovarian endometrioma.

Authors:  Moustafa M Zaitoun; Mohamed Moustafa Zaitoun; Manal M El Behery
Journal:  J Ovarian Res       Date:  2013-11-02       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.